Products for Research Use Only
RegisterLogin

Vamorolone

CAT: 0804-HY-109017-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109017-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vamorolone (VBP15) is a first-in-class, orally active dissociative steroidal anti-inflammatory agent and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone shows potent NF-κB inhibition and substantially reduces hormonal effects[1][2].
CAS Number
13209-41-1
Product Name Alternative
VBP15
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Glucocorticoid Receptor; Mineralocorticoid Receptor; NF-κB
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/vamorolone.html
Purity
99.48
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
C[C@@]12[C@](C(CO)=O)(O)[C@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)C3=CC2)=O
Molecular Formula
C22H28O4
Molecular Weight
356.46
Precautions
H302, H315, H319, H335
References & Citations
[1]Heier CR, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med. 2013 Oct;5 (10) :1569-85.|[2]Dillingham BC, et al. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. Cell Mol Neurobiol. 2015 Apr;35 (3) :377-387.|[3]Heier CR, et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019 Feb 11;2 (1) . pii: e201800186.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
M23477-01Vamorolone
CS-O-54192Vamorolone-D5

Popular Products